Recent

% | $
Quotes you view appear here for quick access.

LG Display Co., Ltd. Message Board

tradevectors 2 posts  |  Last Activity: May 8, 2015 3:27 PM Member since: Jan 24, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tradevectors tradevectors May 8, 2015 3:27 PM Flag

    Mark Kroenke sill twisting research to support short story

    Seeking Alpha deleting commentary to Mark Kroenke (MK) article. Following post, originally submitted 5/6/15 3:22 PM & 6:50 PM to MK's comment of May 6, 2015 9:38 AM was deleted 5/7/15 after 4:00 PM. Three separate requests to repost were made between 8:45 & 9:00 PM 5/7/15 & 4th request 5/7/15 11:25 PM. Original post below w/ MK quotes moved to end. MK refutes some of my assessments but refuses to prove Amgen management did not sanction negative commentary.

    The conclusion to your article and the actions you took to profit encapsulate precisely why immunotherapy has taken so long to develop, and why so many cancer patients have needlessly suffered and died.

    As regards your final comment posted on May 6, 2015 at 09:38 AM, are you saying your article and all of your comments to date regarding NWBO (Northwest Biotherapeutics), DC-Vac-L, DCVax-Direct and dendritic cell-based immunotherapy are or are not sanctioned by Amgen management?

    As you and Amgen are well aware, DCVax-Direct is being tested in melanoma among other indications.

    You claim to be short NWBO. You shamelessly promote your short position by selectively citing research, and maligning NWBO management without identifying your affiliation. Your comments and article demonstrate an utter absence of the scientific rigor and class that as you accuse, is lacking of NWBO and its management, who by the way, individually and collectively, have accomplished more than you will ever accomplish.

    Your article and comments are an insult to the countless medical professionals who over the past 20 years have dedicated their lives to advancing dendritic cell-based immunotherapy. Your work at Amgen better be saturated with the rigor and class that is so apparently absent from your article and comments.

    Prove your short position, and your comments and actions were not sanctioned by Amgen management. Either way, you are a liability and an embarrassment to Amgen

  • Seeking Alpha Editor: Please explain why the following post, which was originally submitted on May 6, 2015 at 3:22 PM and again at 6:50 PM in response to Mark Kroenke's comment of May 6, 2015 9:38 AM, and which was incorrectly posted at 10:03 PM ET as a response to Mark Kroenke's comment of May 45, 2015 5:42 PM was deleted May 7, 2015 after 4:00 PM. Please repost. Thank you.

    The conclusion to your article and the actions you took to profit encapsulate precisely why immunotherapy has taken so long to develop, and why so many cancer patients have needlessly suffered and died.

    "In summary, the safety of DCVax implies the product is terrible at priming T cells since the tumor lysate is overwhelmingly self antigen. In the unlikely event that this is due to perfect immune tolerance in every patient, then the product relies on the generation of an immune response to a mutated antigen, which is a shot in the dark with unfavorable odds. With no defined antigen, identification of responding subgroups will be nearly impossible. Finally, drawing firm conclusions by comparing studies carried out by different organizations in different patients over a course of 15 years is not advisable.

    Don't read this and hit the sell button like a brainless zombie. Think about these 4 points, do your own research, and make a more informed decision. There are plenty of solid biotechnology companies out there that are worthy of your time and investment. It's silly to support a company that uses a control group that was enrolled when Bill Clinton was President."

    As regards your final comment posted on May 6, 2015 at 09:38 AM, are you saying your article and all of your comments to date regarding NWBO (Northwest Biotherapeutics), DC-Vac-L, DCVax-Direct and dendritic cell-based immunotherapy are or are not sanctioned by Amgen management?

    As you and Amgen are well aware, DCVax-Direct is being tested in melanoma among other indications.

    You claim to be short NWBO. You shamelessly promote you

LPL
11.06-0.11(-0.98%)4:01 PMEDT